Effect of IOP Lowering on Progressive HM

Inclusion Criteria: 1. Informed consent given, and consent form signed. 2. Age between 18 and 65 years. 3. Diagnosed with HM: spherical equivalent ≤ -6.00 diopters or AL ≥ 26.5 mm. 4. Progressive HM: progression in AL ≥0.05mm in the past 6 months or ≥0.1mm in the past 12 months. 5. IOP ≥ 10 mmHg and ≤ 21mmHg on at least 2 visits, as measured by Goldmann applanation tonometry . 6. Best corrected visual acuity (BCVA) ≥ 6/12, and being able to obtain adequate AL examination, fundus photographs, optical coherence tomography (OCT) and complete the VF examination. Exclusion Criteria: 1. Allergic to any kind of IOP-lowering therapy. 2. Combination of various serious fundus pathologies, such as proliferative diabetic retinopathy, retinal detachment, central retinal artery occlusion, etc. 3. Combination of chronic, recurrent or severe ocular inflammatory lesions, such as chronic or recurrent uveitis. 4. Patients with significant corneal or iris lesions, or severe cataract affecting fundus examination, or patients with only one eye. 5. Patients who have undergone any surgery or laser treatment affecting eye parameters during the follow-up period (within the last 1 year), such as cataract surgery. 6. Patients with other serious systemic diseases, such as hypertension, heart disease, diabetes, rheumatic immune system disease, etc., who cannot tolerate long-term follow-up and eye treatment. 7. Pregnant or lactating women, or those who plan to have children during the follow-up period.